Basel, Switzerland – October 26, 2023 – In a significant setback for both Novartis and the broader pharmaceutical industry’s efforts to tackle a challenging cardiovascular risk factor, Novartis announced today that its highly anticipated drug, pelacarsen, failed to meet its primary endpoint in a pivotal Phase 3 clinical trial. The HORIZON study, designed to assess the drug’s ability to reduce major adverse cardiovascular events (MACE) in patients with elevated lipoprotein(a) – or Lp(a) – and established cardiovascular disease, did not demonstrate a statistically significant reduction compared to placebo.
n
The news comes as a major blow, particularly given pelacarsen’s prior success in drastically lowering Lp(a) levels, a biomarker long implicated in increased risk for heart attacks, strokes, and other severe cardiac problems. While the drug effectively achieved its intended biological effect of reducing Lp(a) concentrations, this reduction did not translate into the anticipated clinical benefit, raising critical questions about the Lp(a) hypothesis and the future of therapies targeting this elusive risk factor.
n
The Unmet Need: Targeting Lp(a)
n
Lipoprotein(a), often referred to as Lp(a), is a type of low-density lipoprotein (LDL) particle with an added protein called apolipoprotein(a). Elevated levels of Lp(a) are a significant, yet often under-recognized, independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis. Unlike traditional cholesterol markers, Lp(a) levels are largely genetically determined and are not significantly influenced by lifestyle changes or standard lipid-lowering therapies like statins. This genetic predisposition means that individuals with high Lp(a) are at an increased risk of cardiovascular events regardless of their other risk factors, creating a substantial unmet medical need for targeted treatments.
n
For decades, the medical community has grappled with how to effectively lower Lp(a) and, more importantly, whether doing so would translate into tangible clinical benefits for patients. The development of novel therapeutic approaches, such as antisense oligonucleotides (ASOs) like pelacarsen, offered a glimmer of hope. These drugs are designed to specifically inhibit the production of apolipoprotein(a) in the liver, thereby reducing circulating Lp(a) levels.
n
A Journey of Hope and Setback: The Pelacarsen Chronology
n
The journey of pelacarsen, an antisense oligonucleotide developed by Akcea Therapeutics (now Ionis Pharmaceuticals) and licensed to Novartis, has been closely watched by cardiologists, researchers, and investors alike.
n
Early Promise and Mechanism:nPelacarsen’s mechanism of action involves binding to the messenger RNA (mRNA) that codes for apolipoprotein(a), leading to its degradation. This prevents the synthesis of apolipoprotein(a) and, consequently, the formation of Lp(a) particles, resulting in a dose-dependent reduction in plasma Lp(a) levels. In earlier Phase 1 and Phase 2 trials, pelacarsen demonstrated impressive efficacy in lowering Lp(a) levels by as much as 80-90% from baseline, a feat unmatched by any previous therapeutic intervention. These robust biomarker reductions fueled optimism that the drug would finally prove the long-standing Lp(a) hypothesis: that reducing this specific lipoprotein would directly translate into fewer cardiovascular events.
n
The HORIZON Trial Design:nThe pivotal Phase 3 HORIZON study (NCT04023552) was a large-scale, randomized, double-blind, placebo-controlled trial designed to evaluate the clinical efficacy and safety of pelacarsen. It enrolled over 8,000 patients with established cardiovascular disease and elevated Lp(a) levels (≥70 mg/dL or 175 nmol/L). Participants were already receiving optimal standard-of-care lipid-lowering therapy, including statins, and were randomized to receive either pelacarsen or placebo. The primary endpoint was a composite of major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization. The trial aimed to run for several years to accumulate enough cardiovascular events to detect a meaningful difference between the two groups.
n
The Disappointing Announcement:nOn Friday, Novartis issued a concise statement confirming the failure of the HORIZON trial to meet its primary endpoint. The company indicated that while pelacarsen effectively lowered Lp(a) levels, this reduction did not translate into a statistically significant decrease in the risk of cardiovascular death or other major cardiac emergencies like heart attacks or strokes when compared to a placebo. Further detailed data, including subgroup analyses and safety profiles, are expected to be presented at an upcoming scientific conference.
n
Broader Scientific Context and the Lp(a) Conundrum
n
The failure of pelacarsen in HORIZON is a stark reminder of the complexities inherent in cardiovascular drug development. While reducing a biomarker is a necessary step, it does not always guarantee clinical benefit. This outcome forces a re-evaluation of several key assumptions:
n
The Lp(a) Hypothesis: The fundamental premise is that Lp(a) is directly causal in cardiovascular disease. Its atherogenic properties are thought to be similar to LDL cholesterol, promoting plaque formation in arteries. Additionally, Lp(a) has pro-thrombotic and pro-inflammatory effects due to its structural similarity to plasminogen, potentially interfering with fibrinolysis and increasing clot risk. The HORIZON results, however, introduce ambiguity. Does this failure suggest that Lp(a) is merely a marker of risk rather than a direct causative agent whose reduction unequivocally improves outcomes? Or does it imply that the reduction achieved, while substantial, was insufficient, or that the duration of treatment was too short to reverse decades of Lp(a)-driven damage?
n
Genetic vs. Acquired Risk Factors: Lp(a) is largely genetically determined and present from birth. It’s plausible that the long-term exposure to elevated Lp(a) from an early age leads to irreversible damage that therapies initiated in adulthood cannot fully mitigate, even with significant reductions. This contrasts with other risk factors like LDL-C, where interventions can effectively prevent or reverse disease progression.
n
Trial Design and Patient Population: Some experts might question whether the patient population (individuals with established CVD) was too advanced for the intervention to show a benefit, or if the chosen endpoint was sufficiently sensitive. Alternatively, could the effect size simply be smaller than anticipated, requiring an even larger or longer trial?
n
Official Responses and Expert Reactions
n
Novartis’s Stance:nIn its official statement, Novartis expressed disappointment with the HORIZON trial results. "While we are disheartened by the outcome of the HORIZON study, we remain committed to advancing cardiovascular science and addressing unmet needs for patients with cardiovascular disease," a company spokesperson stated. "We will conduct a comprehensive analysis of the full data set to understand these results and determine the next steps for pelacarsen." The company emphasized its continued investment in innovative therapies for complex conditions and thanked the patients, investigators, and trial staff for their participation. The impact on Novartis’s cardiovascular pipeline and R&D strategy will be closely scrutinized in the coming months.
n
Reactions from the Scientific Community:nLeading cardiologists and lipidologists have reacted with a mix of disappointment and cautious reflection. Dr. Jane Smith, a prominent lipid expert at a major academic medical center, commented, "This is certainly a difficult day for the Lp(a) field. Pelacarsen was highly effective at lowering the biomarker, which gave us immense hope. The HORIZON results suggest that merely lowering Lp(a) might not be enough, or perhaps the pathophysiology is more complex than we currently understand. It doesn’t necessarily invalidate Lp(a) as a risk factor, but it forces us to critically examine our therapeutic strategies and the timing of intervention."
n
Another expert, Professor John Doe, head of cardiovascular research at a European university, added, "We need to see the full data, but this raises questions about whether interventions need to start earlier in life for Lp(a), perhaps even before significant atherosclerotic disease has manifested. It also puts more pressure on ongoing trials to demonstrate not just biomarker reduction but true clinical efficacy."
n
Implications for Competing Therapies
n
The failure of pelacarsen sends ripple effects across the biopharmaceutical landscape, particularly impacting other companies developing Lp(a)-lowering therapies. Amgen and Eli Lilly, among others, are also heavily invested in this space, with their own novel drug candidates in various stages of clinical development.
n
Amgen’s Olpasiran:nAmgen’s olpasiran is a small interfering RNA (siRNA) therapeutic designed to inhibit the production of apolipoprotein(a) in the liver, similar in intent to pelacarsen but using a different molecular modality. Olpasiran has shown impressive Lp(a)-lowering capabilities in earlier studies. Its pivotal Phase 3 trial, known as OCEAN(a)-Outcomes, is currently underway. The HORIZON failure will undoubtedly increase scrutiny on the OCEAN(a)-Outcomes trial. Investors and researchers will be keen to see if olpasiran’s siRNA mechanism offers any distinct advantages that might translate into clinical benefit, or if it will face the same challenges as pelacarsen. The design of OCEAN(a)-Outcomes, including patient selection and primary endpoints, will be meticulously compared to HORIZON.
n
Eli Lilly’s Lepodisiran:nEli Lilly is developing lepodisiran, another siRNA therapeutic targeting Lp(a). Early data for lepodisiran has also demonstrated significant and sustained reductions in Lp(a) levels. Lilly’s Phase 3 program is expected to follow. While the molecular mechanism is similar to olpasiran, differences in chemical modifications, dosing regimens, and potentially patient populations could still yield different outcomes. However, the shadow cast by pelacarsen’s failure will undoubtedly increase the bar for success and intensify the pressure on Lilly to demonstrate robust clinical efficacy beyond biomarker reduction.
Other Emerging Therapies:
Beyond ASOs and siRNAs, other investigational approaches to lower Lp(a) exist, though many are in earlier stages. The collective outcome of these trials will be crucial in determining the long-term viability of Lp(a) as a therapeutic target. The pelacarsen news might lead to a more cautious approach from investors and a re-evaluation of pipeline priorities for some companies.
The Road Ahead: Lessons Learned and Future Directions
The failure of Novartis’s pelacarsen in the HORIZON trial is a significant event in cardiovascular medicine. It underscores several critical lessons for drug development:
- Biomarker Reduction vs. Clinical Outcomes: Effectively reducing a biomarker, even a well-established risk factor, does not automatically guarantee improved clinical outcomes. The leap from preclinical and early-phase biomarker data to definitive Phase 3 clinical benefit remains the most challenging hurdle.
- Complexity of Cardiovascular Disease: ASCVD is a multifactorial disease with decades-long progression. Intervening in later stages, even with highly effective agents, may be insufficient to reverse entrenched pathology or prevent acute events.
- The Need for Deeper Understanding: The results necessitate a deeper dive into the specific pathophysiology of Lp(a) and its contribution to disease. Are there specific patient subgroups more likely to benefit? Is there an optimal window for intervention (e.g., earlier in life, before significant disease burden)?
- Trial Design Imperatives: Future trials for novel cardiovascular risk factors may need to consider even longer durations, different patient populations (e.g., primary prevention cohorts), or more sensitive endpoints to detect subtle but clinically meaningful benefits.
For patients with elevated Lp(a), the news is undeniably disappointing. Currently, there are no approved therapies specifically designed to lower Lp(a) and reduce cardiovascular risk. Management largely relies on aggressively treating other conventional risk factors (LDL-C, blood pressure, diabetes) to mitigate overall risk. The scientific community will now turn its attention to the comprehensive data from HORIZON and await the results from ongoing trials, hoping that a different approach or a more nuanced understanding of Lp(a) biology will eventually lead to a breakthrough therapy for this challenging genetic risk factor. The quest to unlock the mysteries of Lp(a) and translate scientific understanding into life-saving treatments continues, albeit with renewed humility and an intensified focus on clinical outcomes.
